BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38235709)

  • 21. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Freise KJ; Jones AK; Eckert D; Mensing S; Wong SL; Humerickhouse RA; Awni WM; Salem AH
    Clin Pharmacokinet; 2017 May; 56(5):515-523. PubMed ID: 27638334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
    Cozad M; Stump SE; Buhlinger K; Collins J; Muir M; Coombs CC; Muluneh B
    Leuk Lymphoma; 2022 Aug; 63(8):1831-1838. PubMed ID: 35262457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
    Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
    Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
    N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
    Eradat H
    Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
    Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
    [No Abstract]   [Full Text] [Related]  

  • 27. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.
    Koehler AB; Leung N; Call TG; Rabe KG; Achenbach SJ; Ding W; Kenderian SS; Leis JF; Wang Y; Muchtar E; Hayman SR; Hampel PJ; Finnes HD; Schwager SM; Slager SL; Kay NE; Parikh SA
    Leuk Lymphoma; 2020 Oct; 61(10):2383-2388. PubMed ID: 32449401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
    Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
    Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
    Olin JL; Griffiths CL; Smith MB
    J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
    Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
    Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
    Eyre TA; Kirkwood AA; Gohill S; Follows G; Walewska R; Walter H; Cross M; Forconi F; Shah N; Chasty R; Hart A; Broom A; Marr H; Patten PEM; Dann A; Arumainathan A; Munir T; Shankara P; Bloor A; Johnston R; Orchard K; Schuh AH; Fox CP;
    Br J Haematol; 2019 May; 185(4):656-669. PubMed ID: 30768675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
    Lampson BL; Davids MS
    Curr Hematol Malig Rep; 2017 Feb; 12(1):11-19. PubMed ID: 28116634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
    N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
    Stephens DM
    Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
    Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
    Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
    [No Abstract]   [Full Text] [Related]  

  • 37. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 39. Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
    Wang L; Lin N
    Medicine (Baltimore); 2021 Feb; 100(6):e24703. PubMed ID: 33578607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
    Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.